๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Qilu Hospital of Shandong University114 Qianfoshan Hospital32 Shandong Cancer Hospital and Institute31 AstraZeneca26 Shandong University26
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jinan

785 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
NCT06778382Colorectal Neoplasms Malignant
Shandong Cancer Hospital and Institute
Phase 2
22
Jinan
2024-06-24
Recruiting
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795Locally Advanced or Metastatic Solid Tumors
DrugANS014004
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
NCT06474468Advanced or Metastatic Esophageal Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
148
Jinan
2024-06-20
Recruiting
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
NCT06368921Solid Tumor
DrugVRT106
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
30
Guangzhou, Zhengzhou, Jinan
2024-06-19
Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
DrugYKST02
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Recruiting
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
NCT06532539Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
DrugsPaclitaxel and Cisplatin·Cadonilimab
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2024-06-13
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
NCT07169656Chronic Hepatitis b
DrugPeginterferon ฮฑ-2b
The First Affiliated Hospital of Zhengzhou University
Observational
15,000
Anyang, Guangzhou, Hebi, Jiaozuo, Jiayuguan, Jinan, Jiyuan, Kaifeng
2024-06-03
Active, closed
Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
NCT06729619Intracranial Infection, Central Infection
Xueyan Cui
Observational
200
Jinan
2024-06-03
Recruiting
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
NCT06420440HCC
DrugsLenvatinib·Tislelizumab
Chen Xiaoping
Phase 2
160
Xiangyang, Jinan
2024-06-01
Active, closed
Risk Factors and Deep Learning Model for CI-AKI
NCT06596785AKI - Acute Kidney Injury
Xiao Li๏ผŒMD
Observational
2,000
Jinan
2024-06-01
Recruiting
Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain
NCT06165991Thoracic Paravertebral Block, Postoperative Analgesia, Thoracoscopic Lobectomy
Yongtao Sun
Phase 4
496
Jinan
2024-06-01
Recruiting
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency
DrugSR604
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
NCT06390774Locally Advanced, Recurrent or Metastatic Malignancies
DrugSSGJ-705
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1
180
Jinan
2024-05-30
Active, closed
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
NCT07131189Locally Advanced/Metastatic Solid Tumors
DrugFL115
Suzhou Forlong Biotechnology Co., Ltd
Phase 1
30
Beijing, Guangzhou, Jinan
2024-05-30
Recruiting
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082Hematological Malignancies
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Not yet open
Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
NCT06421220Gastric Cancer
Qilu Hospital of Shandong University
Not applicable
484
Jinan
2024-05-20
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Not yet open
Effects of Individualized iTBS on Upper Limb Function After Stroke
NCT06147167Upper Extremity Paresis, Stroke
Qilu Hospital of Shandong University
Not applicable
159
Jinan
2024-05-01
Active, closed
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis
NCT06365697Carotid Artery Stenosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
DrugsOsimertinib·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT06251947Ovarian Cancer, Cervical Cancer
DrugEfbemalenograstim alfa
Shandong University
Phase 2
83
Changsha, Nanjing, Jinan, Qingdao, Taiyuan, Hangzhou
2024-04-15
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
DrugsBevacizumab·Tislelizumab
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
By invitation
The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia
NCT06205771Preeclampsia
Hao Feng
Not applicable
54
Jinan
2024-04-10
Recruiting
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
NCT06093932Hypertension,Essential
DrugSongling Xuemaikang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4
100
Beijing, Suzhou, Jinan, Jining, Taiyuan
2024-04-07
Recruiting
Fruquintinib Combined With Sintilimab ยฑ Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT06356584Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
DrugFruquintinib
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
DrugsEquecabtagene Autoleucel·Bortezomib·Pomalidomide·Daratumumab
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Not yet open
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
NCT06300216Neuroendocrine Tumors
Qilu Hospital of Shandong University
Observational
500
Jinan
2024-03-26
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
DrugGR1802
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
Cerebellar Deep Brain Stimulation or VNS for Chronic Post-stroke Motor Rehabilitation
NCT06303960Stroke
Qilu Hospital of Shandong University
Phase EARLY_PHASE1
100
Jinan
2024-03-15
Recruiting
Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
NCT05812287Stomach Neoplasm
Qilu Hospital of Shandong University
Observational
120
Jinan
2024-03-14
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
NCT06292208MTD
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 1/2
48
Jinan
2024-03-09
Recruiting
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
NCT06296563Intrahepatic Cholangiocarcinoma
Lei ZHAO
Phase 2
20
Jinan
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers
NCT07264803Solid Tumor Malignancies, Solid Tumor Cancer
Qilu Hospital of Shandong University
Phase 2
35
Jinan
2024-03-01
Not yet open
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
NCT06335355Non-squamous Non-small Cell Lung Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3
401
Jinan
2024-03
Recruiting
A Clinical Study of AK0610
NCT06996704Healthy Volunteer Study
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 1
136
Jinan
2024-02-29
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai
2024-02-27
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsDisitamab Vedotin·Cadonilimab·Paclitaxel
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Recruiting
Effect of Metformin on Healthy Live Birth in Women With Prediabetes
NCT06064669Metformin, Prediabetes, In-Vitro Fertilization
Shandong University
Not applicable
988
Jinan
2024-02-22
Recruiting
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354Safety, Tolerability, Efficacy
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Active, closed
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAgโ‰ค20IU/ml or HBsAg Negative Without Serological Conversion
NCT07204236Chronic Hepatitis B
DrugTVAX-008
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase EARLY_PHASE1
20
Jinan
2024-01-18
Recruiting
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
NCT06155396Cervical Cancer
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
A Study of AK131 in Patients With Advanced Solid Tumors
NCT06166888Solid Tumor
DrugAK131
Akeso
Phase 1
130
Jinan
2024-01-10
Recruiting
MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients
NCT06197724Non ST Segment Elevation Acute Coronary Syndrome
Qilu Hospital of Shandong University
Observational
14,090
Jinan
2024-01-02
Active, closed
Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
NCT06609759Stage II-III Gastric Cancer
Qilu Hospital of Shandong University
Observational
197
Jinan, Qingdao, Yantai
2024-01-01
Recruiting
Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
NCT06765616Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
DrugAdebrelimab
Feng Tian
Phase 2
31
Jinan
2024-01-01
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
30
Beijing, Wuhan, Jinan, Chengdu
2023-12-30
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
DrugGC012F
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
NCT06196086Heart Failure With Preserved Ejection Fraction
Haiyan Wang
Observational
438
Jinan
2023-12-20
Recruiting
A Study of TAVO412 in Patients with Cancer (TAVO412)
NCT06761651Cancer
DrugTAVO412
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
NCT06171061Chronic Coronary Syndrome
DrugYangxinshi
Shandong First Medical University
Phase 4
1,200
Chongqing, Zhengzhou, Binzhou, Dezhou, Feicheng, Jinan, Liaocheng, Linqing
2023-12-18
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, รœrรผmqi
2023-12-07
Active, closed
Observation of the Therapeutic Effect of Fire Needle on Upper Limb Function in Stroke Patients
NCT07140406Cerebral Infarction
Qilu Hospital of Shandong University
Not applicable
105
Jinan
2023-12-02
Active, closed
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NCT06246344Rectal Cancer
DrugsCapeox·Capecitabine
Shandong Cancer Hospital and Institute
Phase 3
128
Jinan
2023-12-01
Not yet open
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
NCT05965388HBV, HCC
DrugInterferon
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xiโ€™an
2023-12-01
Active, closed
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Haโ€™erbin, Jinan
2023-12-01
Not yet open
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma
DrugsSG001·Cisplatin·Paclitaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
129
Jinan, Tianjin
2023-12
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Recruiting
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
NCT06039735Multiple Myeloma
Qilu Hospital of Shandong University
Observational
50
Jinan
2023-11-16
Recruiting
A Prospective Birth Cohort of Infants With Allergy and Neurodevelopmental Disorders in China
NCT06327906Child Allergy, Neurodevelopmental Disorders
Qilu Hospital of Shandong University
Observational
6,000
Jinan
2023-11-15
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
DrugTislelizumab
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
NCT06699420Coronary Microvascular Disease
Qilu Hospital of Shandong University
Phase 4
162
Jinan
2023-11-08
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
NCT06154538Locally Advanced Colorectal Carcinoma
DrugFolfox
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Recruiting
IN10018 Combination Therapy in Treatment-naรฏve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
DrugsIN10018·Etoposide·Carboplatin·Tislelizumab
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Recruiting
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
NCT06125041Extensive Small Cell Lung Cancer
DrugsEtoposide·Carboplatin
Qianfoshan Hospital
Phase 2
51
Jinan
2023-10-30
Recruiting
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
NCT06904014HCC
DrugsLenvatinib·Tislelizumab
Lei ZHAO
Phase 2
40
Jinan
2023-10-25
Recruiting
A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920Melanoma
DrugIBI363
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
DAREONโ„ข-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Recruiting
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402Multiple Myeloma
DrugElranatamab
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Active, closed
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
NCT06157216Stage II-III Gastric Cancer
Qilu Hospital of Shandong University
Not applicable
65
Jinan, Qingdao, Yantai
2023-10-01
Recruiting
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
NCT06076200Early-Onset Neonatal Sepsis
Shandong University
Observational
50
Jinan
2023-09-30
Active, closed
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
NCT06022250Advanced Malignant Tumor
DrugJS207
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
98
Jinan
2023-09-26
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
NCT06043973Advanced Non-small Cell Lung Cancer
DrugsAlmonertinib·Anlotinib
Qianfoshan Hospital
Phase 3
98
Jinan
2023-09-01
Recruiting
Nalbuphine in ARDS Patients After Surgery
NCT06037330Acute Respiratory Distress Syndrome
Hairong Chen
Phase 4
60
Jinan
2023-09-01
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Active, closed
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
NCT06096896Early Hepatocellular Carcinoma
Shandong Provincial Hospital
Observational
334
Jinan
2023-08-30
Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
NCT06050317Pancreas Cancer
Shandong Cancer Hospital and Institute
Phase 2
25
Jinan
2023-08-18
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Rows per page Showing 501–600 of 785
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 785 of those studies with a site in Jinan.

How many clinical trials are recruiting in Jinan?

488 of the 785 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 130 have not yet opened recruitment, 149 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.